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Abstract
Background and Objectives: We earlier reported elevated chemokine ligand-2 (CCL2) in Indian amyotrophic lateral sclerosis
(ALS) patients. We now analysed chemokine receptor-2 (CCR2), the receptor of CCL2, in these ALS patients.
Methods: Indian sporadic ALS patients (n=50) were included on the basis of El Escorial criteria. Percentage (%) of CCR2
expressing peripheral blood mononuclear cells (PBMCs) was evaluated using Flow Cytometry. Real Time Polymerase Chain
Reaction (PCR) was used to quantitate CCR2 mRNA expression in PBMCs. Normal controls (n=40) were also included for
comparison.
Results: Flow Cytometry revealed significantly reduced CCR2 expressing PBMCs in the ALS patients. We also found a
significant decline in number of CCR2 expressing PBMCs in limb onset ALS when compared to bulbar onset ALS. PBMCs
from ALS patients showed substantial down-regulation of CCR2 mRNA. CCR2 mRNA expression was found to be decreased
among limb ALS patients as compared to bulbar onset ALS. Further, the count of CCR2+ PBMCs and CCR2 mRNA transcript
in PBMCs was significantly lower in severe and moderate ALS as compared to ALS patients with mild impairments.
Conclusions: Downregulation of PBMCs CCR2 may indicate its etio-pathological relevance in ALS pathogenesis. Reduced
PBMCs CCR2 may result in decreased infiltration of leukocytes at the site of degeneration as a compensatory response to
ALS. CCR2 levels measurements in hematopoietic stem cells and estimation of comparative PBMCs count among ALS,
disease controls and normal controls can unveil its direct neuroprotective role. However, the conclusions are restricted by
the absence of neurological/non-neurological disease controls in the study.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease characterized by typical participation of inflammatory
cascade. Interaction of chemokine ligand-2 (CCL2), a small
chemokine belongs to C-C subfamily with its receptor chemokine
receptor-2 (CCR2) strongly regulate these inflammatory changes.
CCL2/CCR2 pathway is known to drive circulating leucocytes
and resident immune cells of brain, including microglial cells,
towards the site of neurodegeneration. Studies have shown that
CCL2 and CCR2 knock out transgenic mouse exhibit reduced
infiltration of blood mononuclear, natural killer cells and dendritic
cells at the site of inflammation and these mice are resistant to
experimental autoimmune encephalomyelitis (EAE) [1,2]. Fur-
thermore, elevated CCL2 levels in biofluids from ALS patients
have been reported earlier [3–13]. Contrary, reduced CCR2
expression in peripheral blood monocytes of ALS patients has also
been observed [7,14] and could be argued as conflicting with
postulated role of CCR2 in inflammation in ALS pathogenesis.
Therefore more studies in other populations with varying clinical
phenotype are imperative to uncover the role of interplay of these
molecules in the ALS disease.
Whether CCL2/CCR2 alteration is neurotoxic or provides
neuroprotection at a given stage of ALS disease remains unclear as
CCL2/CCR2 pathway is also reported to impart neuroprotection
besides mediating inflammation [15,16]. For instance, it has been
demonstrated that CCL2 rescues fetal neurons and astrocytes in a
mixed culture from N-methyl-D-aspartate (NMDA) induced
apoptosis by reducing glutamate and NMDA receptor-1
(NMDAR1) [15]. Additionally, CCL2/CCR2 has also been
reported to prevent HIV-tat induced damage of rat midbrain
neurons [16].
We recently reported higher CCL2 in bio-fluids from Indian
ALS patients and postulated that this may contribute towards
extended survival reported in these patients [12,13]. A major study
from India reported significantly longer survival duration among
ALS patients when compared to Western ALS populations [17].
In this study, we present an indirect evidence of reduced mRNA
and protein CCR2 levels in peripheral blood mononuclear cells
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38382(PBMCs) of Indian ALS patients suggesting its etio-pathological
association with ALS.
Materials and Methods
Ethics Statement
All subjects were included in the study after obtaining written
informed consent as outlined in the research protocol. Ethical
approval for the study was obtained by institute ethical committee,
Post Graduate Institute of Medical Education and Research
(PGIMER), Chandigarh, India–160012 (No. 7055-PG-1Tg-05/
4348-50).
Subjects
Fifty patients, born in North India and diagnosed with ALS by
El Escorial criteria at Neurology outpatient, PGIMER, Chandi-
garh, India were recruited in the study. ALS patients with history
of diabetic neuropathy, glaucoma, pre-eclampsia, stroke and those
receiving Riluzole, anti inflammatory drugs, antioxidants or other
treatment were excluded from the study. The ALS functional
rating score-revised (ALSFRS-R) was measured to evaluate
severity of disease and overall functional status of patients. This
revealed 11 patients which presented with respiratory symptoms
such as orthopnea, dyspnea and other respiratory insufficiencies
even though none of the patients were on respiratory support [18].
At the time of blood collection, 15 ALS patients presented with
mild neurological impairment [ALSFRS-Rrange=36–45;
ALSFRS-Rmean=4060.5(SE)], 30 ALS patients with moderate
impairment [ALSFRS-Rrange=24–36; ALSFRS-
Rmean=32.560.4(SE)] while 5 ALS patients with severe clinical
phenotype [ALSFRS-Rrange=16–24; ALSFRS-
Rmean=18.561.5(SE)] as indicated by ALSFRS-R criteria. The
ALS patients had an overall mean ALSFRS-R score of
34.460.8(SE) with a range of 16 to 45. Disease duration (interval
between appearance of first ALS symptom and sample collection)
for patients with mild, moderate and severe impairments is
reported to be 16.6611.6(SD), 18.4611.9(SD) and
28.8623.0(SD) months respectively. Of 8 bulbar onset ALS
patients, 3 patients exhibited severe neurological impairments and
remaining 5 were presented with moderate impairments. Of 42
limb onset ALS cases, 2 patients were severe, 15 cases were
presented with mild deficit and 25 were presented with moderate
neurological deficit. Based on disease duration, ALS patients were
divided in two groups, disease duration#19 months (n=34) and
disease duration.19 months (n=16). The mean disease duration
of ALS patients was 19.0612.7(SD) months and therefore set as
cutoff. The reference group for comparisons consisted of 40
genetically unrelated; sex and age matched normal controls
without any apparent health problems such as hypertension,
diabetes, heart disease etc. Since there were no neurological
deficits upon examination, the ALSFRS-R score of each normal
control individual was considered as 48. No neurological/
nonneurological disease controls were included in the study. The
clinical details of subjects which are published earlier [12], have
also been reproduced here in Table 1.
PBMCs Isolation
PBMCs were isolated as per Histopaque-1077 (Sigma, USA)
instruction sheet provided by the vendor. Briefly, 6.0 ml blood was
collected from each subject and layered on equal volume of
Histopaque-1077 followed by centrifugation at 1800 rpm for
30.0 mins at room temperature. PBMCs were collected from
plasma/Histopaque-1077 interface. Aliquots of PBMCs were
stored at 280uCi nRNA later (Sigma, USA) until used for total
RNA extraction. Some aliquots of PBMCs was stored in 90% fetal
bovine serum (FBS, HiMedia, India) +10% dimethyl sulphoxide
(DMSO, Sigma, USA) and kept at 280uC until flow cytometry
was done.
RNA Extraction
Total RNA was extracted using RNAeasy columns (Qiagen,
USA). RNA was quantitated by taking absorbance at 260.0 nm.
About 5000.0 ng total RNA was used to synthesize cDNA
according to RevertAid
TM first strand cDNA kit (Fermentas,
USA).
Real Time Polymerase Chain Reaction (PCR)
Real Time PCR was used to quantitate expression of CCR2
mRNA in PBMCs and was performed in the 48 wells version of
Step One
TM (Applied Biosystems Inc., USA) using CCR2 specific
forward (59-AGT TCA GAA GGT ATC TCT CGG TC-39) and
reverse primer (59-GGC GTG TTT GTT GAA GTC ACT-39)
sequences available at primer bank (http://pga.mgh.harvard.edu/
cgi-bin/primerbank). PCR reactions were carried out in duplicates
using SYBR green real time PCR kit (Invitrogen, USA) according
to manufacturer’s recommendations. The cycling conditions
consisted of initial denaturation step for 10.0 mins at 95uC
followed by 40 cycles of denaturation at 95uC for 1.0 min,
annealing at 52uC for 1.0 min and extension at 72uC for 1.0 min.
Relative expression was analyzed using 2
2DDCt or comparative Ct
(threshold cycle) method after normalization with b-actin [4] and
fluorescence data were obtained at annealing step.
Table 1. Characteristics of subjects.
Subjects
{Age (y) M/F (n) Age of onset (y)
{,{Disease duration
(mo)
El Escorial criteria at the time of sample
collection
{Total serum
protein (g/l)
Total ALS 47.4612.4 38/12 46.2612.8 19.0612.7 25 Definite, 15 Probable, 10 Possible 48.2626.7
Limb onset ALS 47.0613.3 33/9 45.5613.8 19.5614.0 20 Definite, 15 Probable, 7 Possible 47.6626.7
Bulbar onset ALS 49.767.5 5/3 48.367.3 15.766.3 5 Definite, 3 Possible 51.6628.4
Normal controls 46.0610.9 30/10 49.9628.2
Clinical details of subjects. ALS, amyotrophic lateral sclerosis; F, female; g, grams; l, litre; n, Number; M, male; mo, months; y, years. Age, age of onset, duration of disease
and total serum protein are indicated as mean 6 standard deviation (SD).
{Duration of disease is the interval between appearance of first symptom of ALS and collection of sample.
{One-way analysis of variance (ANOVA) followed by Fisher’s least significant difference (LSD) post hoc analysis showed that mean age, mean disease duration and mean
total serum protein did not differ significantly among the given conditions (p.0.05). ALS subjects were asked to provide all clinical details at the age of onset of disease.
doi:10.1371/journal.pone.0038382.t001
CCR2 in ALS
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Flow Cytometry was used to study CCR2 protein levels on
PBMCs surface. , 3610
5 PBMCs were blocked with Fc blocker
(1.0 mg, purified human IgG, R&D Systems Inc., USA) +0.1%
sodium azide (Sigma, Germany) +1X Ca
2+ and Mg
2+ free
phosphate buffer saline (PBS, HiMEDIA, India), for 15.0 mins
at room temperature. Cell suspension was then stained with anti-
human CCR2 primary antibody labeled with allophycocyanin
(0.1 mg, R&D Systems Inc., USA) +0.5% bovine serum albumin
(BSA, Sigma, Germany) +0.1% sodium azide +1X PBS for
45.0 mins on ice in dark followed by two washings with 1X PBS at
5,000 rpm for 5.0 mins at 4uC. Finally, the cells were reconstituted
in 250.0 ml of 1X PBS and analyzed in FACSCANTO (BD
Biosciences, USA) flow cytometer using FACS DIVA software
with in 1 hr. Approximately 10,000 viable PBMCs were gated
based on their forward and side scatter profile, and acquired in
each run. PBMCs gate was set to include both lymphocytes and
monocytes where maximum CCR2 fluorescence was observed.
Events outside the PBMCs gate represent cell debris and any
contaminated granulocytes while separating PBMCs from whole
blood. Same gating was used between the experiments. Since
purified population of PBMCs was used during flow cytometry
experiments, no additional surface marker labeling was done to
identify such populations. Background signal was measured for
each sample by acquiring unlabeled PBMCs as negative controls
and normalized to the signal obtained from anit-hCCR2 labeled
PBMCs.
Figure 1. Percentage (%) of CCR2+PBMCs in ALS patients and normal control subjects as measured by Flow Cytometry. (A) Dot plot
showing side and forward scatter analysis of purified unlabeled PBMCs (large combined gate) from a normal control. PBMCs consists of two distinct
populations namely lymphocytes and monocytes. Approximate lymphocytes and monocytes populations are indicated as smaller gates. Events
outside the PBMCs gate represent cell debris and granulocytes. Same gating has been used for PBMCs from each ALS and normal control sample.
,10,000 events have been acquired in each experiment. x-axis represents population cell size in forward scatter (FSC) and y-axis denotes population
cell granularity in side scatter (SSC). (B,C) Single parameter representative histogram of flow cytometric expression pattern of CCR2 on gated PBMCsi s
showing decreased number of CCR2 expressing PBMCs in ALS (9%; C) as compared to normal control (26%; B). Number of cells is represented along
y-axis and blue APC fluorescence along x-axis. Appropriate unlabeled PBMCs were used to set marker in histogram and measure background
fluorescence. (D) Box plot compares CCR2 expressing PBMCs between ALS and normal subjects. Boxes include values from first quartile (25th
percentile) to third quartile (75th percentile). Lower and upper error bar refers to 10th and 90th percentile respectively. The thick horizontal line in the
box represents median for each dataset. Outliers and extreme values are shown in circles and asterisk respectively. Nonparametric Mann Whitney U
test indicates significant difference betweesn the given conditions (p,0.05). ALS, amyotrophic lateral sclerosis; APC, allophycocyanin; CCR2,
chemokine receptor 2; PBMCs, peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0038382.g001
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For skewed data and multiple comparisons, a non-parametric
Kruskal-Wallis H test followed by Mann-Whitney U test was applied.
For skewed data and comparison of two groups, a nonparametric
Mann-Whitney U was used to score the level of significance.
A parametric one-way analysis of variance (ANOVA) followed by
Fisher’s least significant difference (LSD) post hoc test was applied to
compare multiple groups with normal distribution. However, if
data was normally distributed with two groups to compare,
unpaired, independent 2-tailed student t test with equal or unequal
variance (Welch’s correction) was applied. Quantile-quantile (Q-
Q) plot was used to understand whether data is normally
distributed or skewed. Skewed and normally distributed data is
shown as median (10
th percentile 290
th percentile) and mean 6
standard error (SE) respectively. The p-value was considered
significant at #0.05. All statistical analysis was performed by
statistical package and service solution (SPSS) 16 software.
Results
Flow Cytometry analysis of PBMCs of ALS and normal controls
indicates a significant decrease in proportion of CCR2 expressing
PBMCs in ALS patients than normal controls (Figure 1A–1D;
p=0.0001). CCR2 expressing PBMCs were found to be lower in
severe ALS than ALS patients with mild and moderate
neurological impairment (Figure 2A; p=0.006 and p=0.032
respectively). No such difference was observed in ALS patients
with varying duration (Figure 2B; p.0.05). Reduced CCR2+
PBMCs was observed in bulbar and limb variants of ALS as
compared to control group (Figure 2C; p=0.005 and p=0.0001
respectively). Moreover, CCR2+ PBMCs were found to be lower
in limb onset ALS than bulbar onset ALS patients (Figure 2C;
p=0.048). In order to examine any possible association with
hypoxia the CCR2 levels were also analysed in ALS patients with
respiratory dysfunction and those without respiratory dysfunction,
Figure 2. CCR2+ PBMCs in ALS patients with varying clinical characteristics. (A) Percentage (%) of PBMCs expressing CCR2 protein in ALS
patients with mild, moderate and severe neurological impairments as indicated by ALSFRS-R. (B) Count (%) of CCR2+ PBMCs in ALS subjects with
disease duration (DD) #19 months and DD.19 months. (C) Percentage (%) of CCR2 expressing PBMCs in bulbar and limb onset ALS patients. (D)
CCR2+ PBMCs in ALS patients with respiratory dysfunction. In each box plot (A–D), boxes include values from first quartile (25th percentile) to third
quartile (75th percentile). Lower and upper error bar refers to 10th and 90th percentile respectively. The thick horizontal line in the box represents
median for each dataset. Data was collected using Flow Cytometry. A non-parametric Kruskal-Wallis H test followed by Mann Whitney U test was used
to analyze the data. # indicates significant difference among the groups (p,0.05). Outliers and extreme values are shown in circles and asterisk
respectively. ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS functional rating score-revised; CCR2, chemokine receptor 2; DD, disease duration;
PBMCs, peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0038382.g002
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ALS groups (Figure 2D; p.0.05).
Real Time PCR analysis also indicated a 7.1-fold down-
regulation of CCR2 mRNA expression in PBMCs of ALS patients
as compared to normal subjects (Figure 3A–3D; p=0.032). A 27-
fold and 20-fold reduction was observed in severe ALS as
compared to normal and mild ALS respectively (Figure 4A;
p=0.009 and p=0.023 respectively), however, mRNA levels were
comparable across moderate and severe ALS patients (Figure 4A;
p.0.05). In addition, there was no significant reduction of CCR2
mRNA in PBMCs from ALS patients with disease duration .19
months in comparison to ALS patients with #19 months
(Figure 4B; p.0.05). There was a significant decrease of 8.0-fold
in PBMCs CCR2 mRNA in limb onset ALS when compared with
bulbar onset ALS patients (Figure 4C; p=0.009). PBMCs CCR2
transcript expression was comparable between ALS patients with
respiratory dysfunction and without respiratory problems
(Figure 4D; p.0.05).
Discussion
It has earlier been established that chronic activation of PBMCs
via CCL2/CCR2 signaling pathway mediates inflammation in
many neurological disorders. It has been observed that infiltration
of PBMCs in the central nervous system (CNS) of mouse model of
EAE is mediated by CCR2 [19,20]. A profound reduction in
infiltration of leukocytes has been reported around denervated
hippocampus following axonal injury in CCR2 deficient mice
[21]. Mahad et al., showed that the in vitro model of blood-brain
barrier (BBB) was selectively permeable for migrating CCR2+
lymphocytes and monocytes, and suggest the pathological
importance of infiltrated CCR2 expressing PBMCs in multiple
Figure 3. Real Time PCR analysis of relative mRNA expression of CCR2 in PBMCs of subjects. (A) Agarose gel electrophoresis of Real Time
PCR products of target gene CCR2 and endogenous control b-actin. Reactions were performed with mRNA isolated form PBMCs of ALS patient and
normal control. (B) Representative amplification curves depicting increase in fluorescence of CCR2 and b-actin from cDNA of same sample. No
increment in fluorescence of negative controls was observed. The x-axis indicates cycle number and the y-axis shows intensity of relative fluorescence
in linear scale. Ct is threshold cycle where normalized fluorescent signal of SYBR green intersect with threshold line. (C) Melt curve profile of Real Time
PCR products of CCR2 and b actin clearly indicates the absence of any non specific amplification. The x-axis indicates negative derivative of change in
amount of fluorescence per unit change in temperature (dF/dT) and the y-axis represents temperature in Celsius (uC). (D) Bar diagram showing fold
change in CCR2 mRNA expression PBMCs from ALS and normal subjects. Values are plotted as mean 6 SE (Standard error). Data was analyzed by
unpaired, independent 2-tailed student t test with equal variance. # indicates significant difference among the groups (p,0.05). Expression of CCR2
were normalized to expression of endogenous control b-actin. ALS, amyotrophic lateral sclerosis; CCR2, chemokine receptor 2; PBMCs, peripheral
blood mononuclear cells.
doi:10.1371/journal.pone.0038382.g003
CCR2 in ALS
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that the ablation of CCR2 in HexB2/2 mouse model of
Sandhoff disease results in reduced PBMCs infiltration in the brain
parenchyma and ameliorates the clinical progression of the disease
by reducing neuroinflammation, and hence links reduction in
CCR2+ PBMCs with neuroprotection [23]. Increased production
of inflammatory chemokines has recently been reported in PBMCs
of Alzheimer’s disease (AD) patients [24]. With this background,
we measured the levels of CCR2 in PBMCs of Indian ALS
patients as these patients exhibit substantially extended survival
duration of ,115 months after onset of disease [17].
The reduced systemic expression of CCR2 in PBMCs of these
ALS patients reported here suggests its etio-pathological relevance
to ALS pathogenesis. Earlier elevated levels of abnormally
activated and differentiated monocytes/macrophages in sporadic
ALS patients [25] were found to be associated with down
regulation of CCR2 on circulating monocytes [7]. Furthermore,
a significant reduction of CD14+ and CCR2 expressing mono-
cytes in ALS patients, particularly with less severe form of disease,
has been suggested to drive the recruitment of activated monocytes
CNS in the early stages of the disorder [14].
We propose that the decrease in PBMCs CCR2 and previously
reported elevated CCL2 in our ALS patients [12,13] may indicate
an activation of a negative feedback regulation serving to alleviate
the inflammation caused by extravasation of activated monocytes/
lymphocytes at the site of CNS injury and denervated neuromus-
cular junction. Significantly reduced CCR2 levels in moderate and
severe ALS patients and not in mild variants show that CCR2 may
not be causally associated with primary motor neuron degener-
ation and its pathophysiological involvement could be secondary
to neurodegeneration. However, our finding of unaltered CCR2
levels across ALS patients with varying disease duration is
Figure 4. CCR2 mRNA in PBMCs of ALS patients with different clinical states. (A) Relative mRNA expression of CCR2 in PBMCs from ALS
patients with mild, moderate and severe neurological impairments as indicated by ALSFRS-R. (B) Fold change in expression of PBMCs CCR2 mRNA in
ALS subjects with disease duration (DD) #19 months and DD.19 months. (C) Relative CCR2 mRNA expression in PBMCs of bulbar and limb onset ALS
patients. (D) Comparison of PBMCs CCR2 transcripts in ALS patients with respiratory dysfunction. In each bar diagram (A–D), values are plotted as
mean 6 SE (standard error). Data was collected using Real Time PCR and analyzed by one-way analysis of variance (ANOVA) followed by Fisher’s least
significant difference (LSD) post hoc analysis. # indicates significant difference among the groups (p,0.05). Expression of CCR2 was normalized to
expression of endogenous control b-actin. ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS functional rating score-revised; CCR2, chemokine
receptor 2; DD, disease duration; PBMCs, peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0038382.g004
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and actual survival duration after onset of disease. Therefore, at
this time, direct association of reduced CCR2 with extended
survival duration of these ALS patients awaits further analysis
through multi ethnic and multi cultural studies.
Reduced CCR2+ PBMCs in peripheral blood at the time of
sample collection may raise the possibility of their migration and
extravasation in CNS through damaged blood-brain barrier (BBB)
and blood-spinal cord barrier (BSCB) in ALS pathogenesis
[26,27,28,29], however, anatomical and histopathological analysis
of BBB and BSCB was not conducted. Our report, therefore,
suggests the need of future autopsy studies where brain and spinal
cord tissue from Indian ALS patients can be analysed for presence
of CCR2+ PBMCs. The massive infiltration of immature blood
dendritic cells, CD4+ and CD8+ T-lymphocytes in spinal cord
parenchyma has earlier been observed in Western ALS cases [4]
and in superoxide dismutase 1 (SOD1) mutated transgenic ALS
mouse model [30].
The unaltered levels of total serum protein in the ALS patients
studied (Table 1) suggest that these findings are specific to CCR2+
PBMCs. However the expression of CCR2+ immune cells other
than PBMCs including natural killer cells, dendritic cells and
macrophages in these patients were not separately performed.
Significantly elevated PBMCs CCR2 in bulbar ALS versus limb
variant appears to be in contrast to the theory developed in the
paper. For instance, the overall functional deterioration was found
to be higher in bulbar [Mean ALSFRS-R=28.763.2(SE)] when
compared to the limb ALS [Mean ALSFRS-R=35.460.8(SE)].
We speculate that higher levels of PBMCs CCR2 reported in
bulbar variants may result from reduced disease duration and
severity of these cases. Hence, future longitudinal studies for
estimation of PBMCs CCR2 in higher number of bulbar Indian
ALS patients and its possible association with clinical progression
of the ALS disease may provide useful information about role of
CCR2 in ALS. Since lower PBMCs CCR2 may facilitate
neuroprotection, at the moment, lower CCR2 levels among limb
ALS than bulbar ALS patients may account for relatively slower
progression of disease and longer survival duration in limb ALS
cases [17,31]. These findings are consistent with existing literature
where limb Indian ALS patients were reported to exhibit
significantly higher median survival duration [177.963.2(SE)]
after disease onset as compared to bulbar group [55.962.9(SE)]
[17].
We further propose that the downregulation of CCR2 mRNA
in ALS subjects may indicate the underlying genetic/epigenetic
abnormalities in regulatory elements of CCR2 gene including its
post transcriptional deregulation necessitating detailed analysis of
CCR2 domain in ALS population. CCR2 reduction in response to
environmental cues can also not be ruled out in present ALS
patients. Even though respiratory dysfunction did not impact
CCR2 levels in the present study (Figure 2D & 4D), role of
respiratory impairment should be addressed in larger ALS cohort
with respiratory complications as downregulation of monocytic
CCR2 under hypoxia has earlier been observed in in vitro
conditions [32].
Because of lack of neurological disease controls having
overlapping or distinct clinical symptoms with ALS, the differences
observed in CCR2 levels in the study may reflect the molecular
change relevant to diseases of CNS in general, as opposed to ALS
disease in specific. Therefore, the absence of such control group is
an important caveat of the study and further investigations should
focus on the use of neurological controls in the analysis.
In conclusion, although causal association of reduced CCR2
with increased survival in Indian ALS patients remains specula-
tive, the present findings may suggest an etio-pathological and
possible immunomodulatory importance of PBMCs CCR2 in
pathogenesis of ALS. Whether the blocking or reducing glial and
leukocyte CCR2 (by intracerebral and/or systemic injection of its
antagonists or synthetic siRNA against CCR2 mRNA) will lead to
any therapeutic efficacy in ALS will be determined by further
preclinical studies.
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